| Literature DB >> 30406022 |
Asieh Karimani1, Amir Hooshang Mohammadpour2,3, Mohammad Reza Zirak1, Ramin Rezaee4, Bruno Megarbane5, Aristidis Tsatsakis6, Gholamreza Karimi1,3.
Abstract
Aluminum phosphide (AlP), an inexpensive solid fumigant, is frequently used for grain conservation despite its alleged high toxicity. Increased utilization of AlP for agricultural and non-agricultural purposes during the last four decades has resulted in increment of AlP-attributed poisoning numbers. Moreover, due to its limitless accessibility in developing countries, AlP has been increasingly used for suicide. Moisture-exposed AlP undergoes a chemical reaction producing phosphine gas, which in turn inhibits cytochrome oxidase and impedes cellular oxygen consumption. Lethality remains elevated reaching rates of >50% and no effective antidote is available. Nevertheless, experimental and clinical studies suggested that magnesium sulfate, melatonin, N-acetylcysteine, glutathione, sodium selenite, vitamin C and E, triiodothyronine, liothyronine, vasopressin, milrinone, Laurus nobilis L., 6-aminonicotinamide, boric acid, acetyl-L-carnitine and coconut oil, may serve as antidotes by reducing the deleterious oxidative properties of AlP. This article reviews the afore-mentioned chemicals suggested to specifically treat AlP poisoning and discusses their protective mechanisms and main outcomes.Entities:
Keywords: Aluminum phosphide; Antidote; Intoxication; Phosphine; Protection
Year: 2018 PMID: 30406022 PMCID: PMC6214862 DOI: 10.1016/j.toxrep.2018.10.009
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Fig. 1Pathophysiology of aluminum phosphide (AlP) intoxication. After ingestion, AlP reacts with stomach acid and releases phosphine (PH3) gas. PH3 reaches the heart through the systemic circulation and causes myocardial cell death and arrhythmias.
Antidotes studied for treatment of AlP intoxication.
| Treatment | Experimental model | Dose/route of AlP | Dose/route | Main findings |
|---|---|---|---|---|
| Magnesium sulfate | Human study | – | – | Improved oxidative stress status |
| Melatonin | 0.25-2 mM | 0.1-2mM | Antioxidant activity | |
| Animal study (Rats) | 4 mg/kg IP | 10 mg/kg IP | ||
| Animal study (Rats) | 16.7 mg/kg | 40-50 mg/kg IP | ||
| Animal study (Rats) | 2 mg/kg | 10 mg/kg IP | ||
| Coconut oil | Human study | 12 g | Oral | Increased survival rate |
| N-acetyl cysteine | Animal study (Mice) | 10-20-40 mg/kg IP | 50-100 mg/kg IP | Delaying the latency of death |
| Animal study (Rats) | 12.5 mg/kg | 6.25 mg/kg/min Infusion for 30 min | Improvement of hemodynamic profile and biochemical parameters | |
| Human study | – | 140 mg/kg infusion (loading dose) | Reduction of the duration of hospitalization and mechanical ventilation | |
| Case report | – | 300 mg/kg infusion for 20 h | Improvement of cardiac alteration | |
| Sodium selenite | Animal study (Mice) | 10-20-40 mg/kg IP | 3 mg/kg | Reduction of pulmonary and liver complications |
| Vitamin E | Case report | 3 g | 400 units IM | Decrement of mechanical ventilation duration |
| Triiodothyronine | Animal study (Rats) | 12 mg/kg | 3 μg/kg | Improvement of cardiovascular complications |
| Liothyronine | Human study | 50 μg oral | Amelioration of cardiac complications and oxidative stress | |
| Vasopressin | Animal study (Rats) | 12.5 mg/kg gavage | 2 IU/kg IP | Cardio protective effects |
| Milrinone | Animal study (Rats) | 12.5 mg/kg gavage | 0.25 mg/kg | |
| 58 mg/l | 25, 50, 100 and 200 mg/l | Decrement of oxidative stress | ||
| Animal study (Rats) | – | 200 mg/kg for 14 days, IP | Suppression of genetic damage | |
| 6-aminonicothinamide | – | 3 μg/ml for 2 h | Decrement of ROS formation and lipid peroxidation | |
| Boric acid | 1 g/200 ml | Saturated boric acid solution | Decrement of the grade of gas evolution | |
| Acetyl-l-carnitine | Animal study (Rats) | – | 100, 200, 300 mg/kg, IP | Increment of cytochrome oxidase and ATP production |
IV: intravenous, IM: intramuscular and IP: intraperitoneal.